









市場
/
株式
/
nasdaq-dvax
/

Dynavax Technologies Corp

DVAX

15.380USD

+4.250+38.19%

終値 12/24, 13:00（ET）15分遅れの株価

1.81B時価総額

損失額直近12ヶ月PER



Dynavax Technologies Corp

15.380

+4.250+38.19%

概要企業名金融分析

概要

企業名

金融

分析

詳細情報 Dynavax Technologies Corp 企業名

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Dynavax Technologies Corpの企業情報



企業コードDVAX

会社名Dynavax Technologies Corp

上場日Feb 19, 2004

最高経営責任者「CEO」Spencer (Ryan)

従業員数405

証券種類Ordinary Share

決算期末Feb 19

本社所在地2100 Powell Street

都市EMERYVILLE

証券取引所NASDAQ OMX - NASDAQ BASIC

国United States of America

郵便番号94608

電話番号15108485100

ウェブサイトhttps://www.dynavax.com/

企業コードDVAX

上場日Feb 19, 2004

最高経営責任者「CEO」Spencer (Ryan)

Dynavax Technologies Corpの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Ryan Spencer

Chief Executive Officer, Director

277.67K

Dr. Robert (Rob) Janssen, M.D.

Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs

74.92K

Mr. David F. Novack

Chief Operating Officer, Senior Vice President

56.05K

+33.36%

Mr. John L. Slebir

Senior Vice President, General Counsel

31.42K

Ms. Elaine D. Sun

Independent Director

29.86K

+23.89%

Ms. Kelly MacDonald, CPA

Chief Financial Officer, Senior Vice President

25.52K

Dr. Peter R. Paradiso, Ph.D.

Independent Director

24.83K

+30.19%

Dr. Daniel L. (Dan) Kisner, M.D.

Independent Director

23.33K

+32.77%

Mr. Brent MacGregor

Independent Director

21.83K

+35.83%

Dr. Emilio Emini

Independent Director

1.44K

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Ryan Spencer

Chief Executive Officer, Director

277.67K

Dr. Robert (Rob) Janssen, M.D.

Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs

74.92K

Mr. David F. Novack

Chief Operating Officer, Senior Vice President

56.05K

+33.36%

Mr. John L. Slebir

Senior Vice President, General Counsel

31.42K

Ms. Elaine D. Sun

Independent Director

29.86K

+23.89%

Ms. Kelly MacDonald, CPA

Chief Financial Officer, Senior Vice President

25.52K

収益内訳

通貨: USD更新時刻: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

事業別USD

会社名

収益

比率

HEPLISAV-B

91.87M

96.26%

Other revenue

3.57M

3.74%

地域別USD

会社名

収益

比率

93.57M

98.04%

Non-US

1.88M

1.96%

事業別

地域別

事業別USD

会社名

収益

比率

HEPLISAV-B

91.87M

96.26%

Other revenue

3.57M

3.74%

株主

更新時刻: Sun, Nov 16

株主統計

種類

株主統計

比率

Deep Track Capital LP

13.39%

BlackRock Institutional Trust Company, N.A.

12.52%

The Vanguard Group, Inc.

6.88%

State Street Investment Management (US)

5.35%

Millennium Management LLC

3.86%

他の

58.00%

株主統計

比率

Deep Track Capital LP

13.39%

BlackRock Institutional Trust Company, N.A.

12.52%

The Vanguard Group, Inc.

6.88%

State Street Investment Management (US)

5.35%

Millennium Management LLC

3.86%

他の

58.00%

種類

株主統計

比率

Investment Advisor

36.25%

Hedge Fund

33.74%

Investment Advisor/Hedge Fund

21.02%

Research Firm

6.07%

Pension Fund

1.18%

Individual Investor

0.60%

Bank and Trust

0.40%

Private Equity

0.04%

Sovereign Wealth Fund

0.03%

他の

0.67%

機関投資家保有株



更新時刻: Mon, Dec 8

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q4

546

115.83M

109.38%

+66.95K

2025Q3

565

115.78M

113.44%

+813.17K

2025Q2

563

116.95M

120.36%

-13.51M

2025Q1

558

131.20M

118.77%

-16.39M

2024Q4

550

133.28M

116.08%

-4.50M

2024Q3

545

132.56M

115.53%

-2.40M

2024Q2

531

134.71M

114.10%

-1.03M

2024Q1

527

135.87M

107.19%

-4.14M

2023Q4

514

128.04M

106.45%

-253.89K

2023Q3

500

128.23M

106.72%

-886.82K

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

Deep Track Capital LP

15.73M

13.41%

-2.07M

-11.61%

Aug 22, 2025

BlackRock Institutional Trust Company, N.A.

15.80M

13.47%

-2.85M

-15.27%

Jun 30, 2025

The Vanguard Group, Inc.

8.40M

7.17%

-266.13K

-3.07%

Jun 30, 2025

State Street Investment Management (US)

6.40M

5.45%

-394.51K

-5.81%

Jun 30, 2025

Millennium Management LLC

1.61M

1.38%

+1.39M

+612.12%

Jun 30, 2025

Chicago Capital, LLC

5.23M

4.46%

-116.66K

-2.18%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

3.64M

3.11%

-365.20K

-9.11%

Jun 30, 2025

Renaissance Technologies LLC

2.89M

2.46%

+181.00K

+6.69%

Jun 30, 2025

Two Sigma Investments, LP

3.80M

3.24%

+1.53M

+67.74%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.69M

2.29%

-377.05K

-12.30%

Jun 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

種類

比率

データなし

日付

種類

比率

データなし

よくある質問

Dynavax Technologies Corpの上位5名の株主は誰ですか？



Dynavax Technologies Corpの上位5名の株主は以下のとおりです。
Deep Track Capital LPは15.73M株を保有しており、これは全体の13.41%に相当します。
BlackRock Institutional Trust Company, N.A.は15.80M株を保有しており、これは全体の13.47%に相当します。
The Vanguard Group, Inc.は8.40M株を保有しており、これは全体の7.17%に相当します。
State Street Investment Management (US)は6.40M株を保有しており、これは全体の5.45%に相当します。
Millennium Management LLCは1.61M株を保有しており、これは全体の1.38%に相当します。